Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.

被引：0
|
作者：
Gilbert, Lucy
Oaknin, Ana
Matulonis, Ursula A.
Mantia-Smaldone, Gina
Lim, Peter C.
Castro, Cesar Martin
Provencher, Diane M.
Memarzadeh, Sanaz
Wang, Jiuzhou
Esteves, Brooke
Zweidler-McKay, Patrick A.
Moore, Kathleen N.
O'Malley, David M.
机构：
[1] McGill Univ, Royal Victoria Hosp, Hlth Ctr, Montreal, PQ, Canada
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[5] Renown Reg Med Ctr, Ctr Hope, Reno, NE USA
[6] Harvard Med Sch, Massachusetts Gen Hosp, Reading, MA USA
[7] Univ Montreal, Montreal, PQ, Canada
[8] Univ Calif Los Angeles, Los Angeles, CA USA
[9] ImmunoGen Inc, Waltham, MA USA
[10] Kadmon Rsrch Inst, Wilmington, MA USA
[11] ImmunoGen, Waltham, MA USA
[12] Univ Oklahoma, Med Ctr, Oklahoma City, OK USA
[13] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6004
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.
    O'Malley, David M.
    Oaknin, Ana
    Matulonis, Ursula A.
    Mantia-Smaldone, Gina
    Lim, Peter C.
    Castro, Cesar Martin
    Provencher, Diane M.
    Memarzadeh, Sanaz
    Zweidler-McKay, Patrick A.
    Wang, Jiuzhou
    Esteves, Brooke
    Moore, Kathleen N.
    Gilbert, Lucy
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate, in Combination With Bevacizumab in Patients With Platinum-Agnostic Ovarian Cancer: Final Analysis
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 8 - 10
  • [3] Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
    Gilbert, Lucy
    Oaknin, Ana
    Matulonis, Ursula A.
    Mantia-Smaldone, Gina M.
    Lim, Peter C.
    Castro, Cesar M.
    Provencher, Diane
    Memarzadeh, Sanaz
    Method, Michael
    Wang, Jiuzhou
    Moore, Kathleen N.
    O'Malley, David M.
    GYNECOLOGIC ONCOLOGY, 2023, 170 : 241 - 247
  • [4] Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
    O'Malley, David M.
    Matulonis, Ursula A.
    Birrer, Michael J.
    Castro, Cesar M.
    Gilbert, Lucy
    Vergote, Ignace
    Martin, Lainie P.
    Mantia-Smaldone, Gina M.
    Gonzalez Martin, Antonio
    Bratos, Raquel
    Penson, Richard T.
    Malek, Karim
    Moore, Kathleen N.
    GYNECOLOGIC ONCOLOGY, 2020, 157 (02) : 379 - 385
  • [5] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.
    O'Malley, David M.
    Matulonis, Ursula A.
    Birrer, Michael J.
    Castro, Cesar Martin
    Vergote, Ignace
    Martin, Lainie P.
    Mantia-Smaldone, Gina
    Gilbert, Lucy
    Gonzalez-Martin, Antonio
    Bratos, Raquel
    Esteves, Brooke
    Malek, Karim S.
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer
    O'Malley, D. M.
    Richardson, D. L.
    Vergote, I. B.
    Gilbert, L.
    Castro, C.
    Provencher, D.
    Matulonis, U. A.
    Mantia-Smaldone, G.
    Martin, L.
    Zweidler-Mckay, P. A.
    Moore, K. N.
    ANNALS OF ONCOLOGY, 2020, 31 : S626 - S627
  • [7] Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer
    O'Malley, D.
    Richardson, D.
    Vergote, I. B.
    Gilbert, L.
    Martin, L. P.
    Mantia-Smaldone, G. M.
    Castro, C.
    Provencher, D.
    Matulonis, U. A.
    Malek, K.
    Moore, K. N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer
    Richardson, Debra L.
    Moore, Kathleen N.
    Vergote, Ignace
    Gilbert, Lucy
    Martin, Lainie P.
    Mantia-Smaldone, Gina M.
    Castro, Cesar M.
    Provencher, Diane
    Matulonis, Ursula A.
    Stec, James
    Wang, Yuemei
    Method, Michael
    O'Malley, David M.
    GYNECOLOGIC ONCOLOGY, 2024, 185 : 186 - 193
  • [9] IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum resistant epithelial ovarian cancer (EOC) patients (pts).
    Moore, Kathleen N.
    Martin, Lainie P.
    Matulonis, Ursula A.
    Konner, Jason A.
    Seward, Shelly Marie
    Bauer, Todd Michael
    O'Malley, David M.
    Perez, Raymond P.
    Jeong, Woondong
    Zhou, Yinghui
    Kirby, Maurice William
    Mohanavelu, Satishkumar
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.
    O'Malley, David M.
    Martin, Lainie P.
    Gilbert, Lucy
    Vergote, Ignace
    Matulonis, Ursula A.
    Birrer, Michael J.
    Castro, Cesar Martin
    Malek, Karim S.
    Gonzalez-Martin, Antonio
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345